Fr. 146.00

Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants - New Vistas In Parkinson's Disease Therapy

English · Paperback / Softback

Shipping usually within 1 to 2 weeks (title will be printed to order)

Description

Read more

The specific topic, "Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants - New Perspectives In Parkinson`S Disease Therapy," was chosen in light of accumulating neurobiological evidence indicating that, in addition to exogenous neurotoxins (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP]), endogenous compounds may play an important role in the most common neurodegenerative disorders (e.g., Parkinson`s disease). Two groups of amine related compounds, which appeared chemically like MPTP, were detected in human brain and cerebrospinal fluid (CSF): ß-carbolines (BCs) and tetrahydroisoquinolines (TIQs). These are heterocyclic compounds formed endogenously from phenylalanine/tyrosine (TIQs) and tryptophan, tryptamine, and 5-hydroxytryptamine (BCs), respectively and exert a wide spectrum of psychopharmacological and behavioral effects. The TIQs and BCs may bind to their own high affinity sites on neuronal membranes associated with or located close to the receptors of neurotransmitters. Research on TIQs and BCs is stimulated also by their possible role in pathological conditions, especially parkinsonism and alcoholism. Recently, clinical interest has been spurred by their role as neuroprotective, and even neurorestorative, anticonvulsant and antiaddictive, substances.

In this book we are going to summarize, for the first time, the results from behavioral, neurochemical and molecular experiments, which demonstrate a wide spectrum of TIQs and BCs effects - from their rather mild neurotoxic actions to the important neuroprotective and antiaddictive properties.

Additionally, the recent results of experimental studies in vivo have allowed a much better understanding and simultaneous comparison of the neurochemical and molecular mechanisms underlying the neuroprotective and neurotoxic actions of endogenous TIQs and BCs and have pointed to the possibility oftheir therapeutic applications in neurodegenerative diseases such as Parkinson's disease.

List of contents

Two faces of 1,2,3,4-tetrahydroisoquinoline mode of action in the mammalian brain: is it an endogenous neurotoxin or a neuromodulator?.- Isoquinolines as a neurotoxins: action and molecular mechanism.- 1-Methyl-1,2,3,4-tetrahydroisoquinoline - a potent neuroprotecting agent.- 1-Methyl-1,2,3,4-tetrahydroisoquinoline and addiction: experimental studies.- Beta-carbolines as neurotoxins.- Neuroprotective beta-carbolines: occurrence, formation and biodegradation.- Beta-carbolines and neuroprotection: inhibition of monoamine oxidase.- Beta-carbolines increase the efficiency of the respiratory chain in mitochondria.- Antioxidant properties of beta-carbolines.- Restoration of neuronal functions in damaged dopamine neurons: in vitro and in vivo studies.- Prospects for new treatment options in neurodegenerative diseases.

Summary

       The specific topic, “Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants – New Perspectives In Parkinson`S Disease Therapy,” was chosen in light of accumulating neurobiological evidence indicating that, in addition to exogenous neurotoxins (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP]), endogenous compounds may play an important role in the most common neurodegenerative disorders (e.g., Parkinson`s disease). Two groups of amine related compounds, which appeared chemically like MPTP, were detected in human brain and cerebrospinal fluid (CSF): ß-carbolines (BCs) and tetrahydroisoquinolines  (TIQs). These are heterocyclic compounds formed endogenously from phenylalanine/tyrosine (TIQs) and tryptophan, tryptamine, and 5-hydroxytryptamine (BCs), respectively and exert a wide spectrum of psychopharmacological and behavioral effects. The TIQs and BCs may bind to their own high affinity sites on neuronal membranes associated with or located close to the receptors of neurotransmitters. Research on TIQs and BCs is stimulated also by their possible role in pathological conditions, especially parkinsonism and alcoholism. Recently, clinical interest has been spurred by their role as neuroprotective, and even neurorestorative, anticonvulsant and antiaddictive, substances.
           
In this book we are going to summarize, for the first time, the results from behavioral, neurochemical and molecular experiments, which demonstrate a wide spectrum of TIQs and BCs effects - from their rather mild neurotoxic actions to the important neuroprotective and antiaddictive properties.
Additionally, the recent results of experimental studies in vivo have allowed a much better understanding and simultaneous comparison of the neurochemical and molecular mechanisms underlying the neuroprotective and neurotoxic actions of endogenous TIQs and BCs and have pointed to the possibility oftheir therapeutic applications in neurodegenerative diseases such as Parkinson's disease.

Product details

Assisted by Lucyn Antkiewicz-Michaluk (Editor), Lucyna Antkiewicz-Michaluk (Editor), Rommelspacher (Editor), Rommelspacher (Editor), Hans Rommelspacher (Editor)
Publisher Springer, Berlin
 
Languages English
Product format Paperback / Softback
Released 03.04.2014
 
EAN 9781489987549
ISBN 978-1-4899-8754-9
No. of pages 178
Dimensions 160 mm x 235 mm x 11 mm
Weight 296 g
Illustrations X, 178 p.
Series Current Topics in Neurotoxicity
Current Topics in Neurotoxicity
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

B, Neuroscience, Neurology & clinical neurophysiology, Neurosciences, Pharmacy, Biomedical and Life Sciences, Neurochemistry, Pharmacy / dispensing

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.